10-Q: Pharma-Bio Serv Reports Q2 2026 Results, Net Income Rises

Pharma-Bio Serv, Inc. announced its financial results for the second quarter of fiscal year 2026, reporting an increase in net income and revenues, driven by growth in its Puerto Rico consulting segment.

Summary

• Pharma-Bio Serv, Inc. reported revenues of $2.70 million for the three months ended April 30, 2026, an increase from $2.42 million in the same period last year.
• Net income for the quarter was $232,986, a significant increase from $95,353 in the prior year's quarter.
• For the six-month period ended April 30, 2026, revenues were $5.00 million, up from $4.89 million in the prior year.
• Net income for the six-month period was $265,846, compared to $103,889 in the prior year.
• The company's Puerto Rico consulting segment showed strong performance, while the US consulting segment experienced a decline.
• Selling, general, and administrative expenses decreased by approximately $0.2 million in both the three-month and six-month periods compared to the prior year, attributed to reduced occupancy expenses and other planned savings.
• The company had approximately $10.2 million in working capital as of April 30, 2026.
• The company repurchased 4,300 shares of its common stock during the six-month period ended April 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with clear improvements in net income and revenue, alongside successful cost reductions. However, the ongoing legal proceedings and customer concentration risks temper the overall sentiment.

Positives

• Revenue increased by approximately $0.28 million for the three months ended April 30, 2026, compared to the same period last year.
• Net income for the three months ended April 30, 2026, increased by approximately $0.14 million compared to the same period last year.
• Revenue for the six months ended April 30, 2026, increased by approximately $0.11 million compared to the same period last year.
• Net income for the six months ended April 30, 2026, increased by approximately $0.16 million compared to the same period last year.
• Selling, general, and administrative expenses decreased by approximately $0.16 million for the three months ended April 30, 2026, compared to the same period last year.
• Selling, general, and administrative expenses decreased by approximately $0.20 million for the six months ended April 30, 2026, compared to the same period last year.
• The company has a strong working capital position of approximately $10.2 million as of April 30, 2026.
• The company continues to repurchase shares under its stock repurchase program.

Negatives

• The United States consulting market experienced a decline in project revenue by approximately $0.1 million for the three months ended April 30, 2026, compared to the same period last year.
• The United States consulting market experienced a decline in project revenue by approximately $0.2 million for the six months ended April 30, 2026, compared to the same period last year.
• The company is involved in a significant legal proceeding related to a breach of contract, with a judgment of over $6.7 million awarded to its subsidiaries, though collection is uncertain.
• The company's reliance on a few key customers for a significant portion of its revenue (54.6% in Q2 2026) presents a concentration risk.

Risks

• Regional or global conflicts, including war and economic sanctions between nations, price inflation, and pandemics, may adversely affect future performance.
• Possible tax changes in jurisdictions where the company does business could impact financial results.
• Bio-pharmaceutical industry consolidations and relocations may affect demand for services.
• Trends in managing contract resources and operational constraints imposed by customers due to pandemics could impact operations.
• The company has not received a status update from PRIDCO regarding its request to extend its tax grant, although it does not anticipate significant concerns.
• The company is pursuing collection of a significant judgment against Romark Global Pharma, LLC, but collection is uncertain due to Romark's financial situation and claims from other creditors.

Future Outlook

Management believes that its current working capital, operations, and cash flows from operations, along with the collectability of receivables, are sufficient to fund anticipated expenses and contractual commitments for the next twelve months. The company is actively seeking to renegotiate its tax grant with PRIDCO and does not anticipate significant concerns with its approval. The company's future profitability and liquidity are dependent on the global economy, potential conflicts, inflation, pandemics, tax law changes, industry consolidations, and customer operational constraints.

Management Comments

• The company vetted various technologies which resulted in moving its headquarters administrative operations to a virtual landscape, enabling the maintenance of the same level of service in a more competitive manner.
• Management is not aware of any other trends or events likely to have a material adverse effect on liquidity or its financial statements, despite uncertainties in the economic and regulatory environment.

Industry Context

StockSavvy.ai notes that Pharma-Bio Serv operates in the technical compliance consulting sector, serving the pharmaceutical, chemical, biotechnology, medical devices, cosmetics, and food industries. The company faces competition from local and international firms. The shift towards virtual operations for administrative functions aligns with broader industry trends of leveraging technology for efficiency and cost-effectiveness.

Comparison to Industry Standards

• The company's gross profit margin for the six months ended April 30, 2026, was 32.5%, which is generally in line with or slightly above the typical margins for specialized consulting services in regulated industries, though specific industry benchmarks are not provided in the filing.
• The company's SG&A expenses as a percentage of revenue for the six months ended April 30, 2026, were 31.5%, which is a reduction from 36.4% in the prior year, indicating improved operational efficiency. This reduction is a positive step, though direct comparison to industry peers would require more detailed data on their operational structures and cost bases.

Legal Proceedings

• Pharma-Bio Serv's subsidiaries filed a breach of contract and money collection complaint against Romark Global Pharma, LLC, Romark Properties, LLC, Romark Biosciences, LLC, and Romark Holdings, LLC. A judgment was entered ordering Romark to pay $6,717,431.69, but collection is uncertain as the company has been unable to identify assets of Romark against which to collect, and other creditors have filed claims.

Stakeholder Impact

• Shareholders may benefit from the increase in net income and earnings per share, as well as the ongoing share repurchase program.
• Employees are likely to continue to benefit from the company's stable operations and focus on maintaining service levels, even with the shift to a virtual administrative model.
• Customers in the pharmaceutical, chemical, medical device, and biotechnology industries will continue to receive technical compliance consulting services, with the company adapting its operational model for efficiency.

Next Steps

• The company is pursuing avenues for collection of the judgment against Romark Global Pharma, LLC.
• The company has requested PRIDCO to extend its tax grant for an additional fifteen years and is awaiting a status update.
• The company will continue to monitor and adapt to global economic conditions, tax law changes, and industry trends.

Key Dates

Recommendation

The company shows positive trends in revenue and profitability, along with effective cost management. However, the significant legal judgment with uncertain collection, coupled with customer concentration risks, warrants a cautious approach. A 'hold' recommendation is appropriate pending further clarity on the legal proceedings and sustained performance across all segments.

Keywords

Pharma-Bio Serv, 10-Q, Quarterly Report, Consulting Services, Pharmaceutical Industry, Puerto Rico, United States, Europe, Financial Results, Revenue, Net Income, SEC Filing